Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

No association of prior administration of selected vaccines with lymphoma prognosis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis.

Blood cancer journal·2026
Same author

Racial/Ethnic Disparities in Neoplasm-Related Mortality and the Social Determinants of Health.

Cancers·2026
Same author

Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.

British journal of haematology·2026
Same author

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes.

American journal of hematology·2026
Same journal

Adult acute lymphoblastic leukemia: incorporation of recent advances into current treatment strategies.

Blood cancer journal·2026
Same journal

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial.

Blood cancer journal·2026
Same journal

Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma.

Blood cancer journal·2026
Same journal

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Blood cancer journal·2026
Same journal

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma.

Blood cancer journal·2026
Same journal

Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.

Blood cancer journal·2026
查看所有相关文章

相关实验视频

Updated: Mar 11, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K

目前的治疗算法:扩散大B细胞淋巴瘤.

Stephen M Ansell1, Grzegorz S Nowakowski2

  • 1Division of Hematology, Mayo Clinic, Rochester, MN, USA. Ansell.stephen@mayo.edu.

Blood cancer journal
|March 10, 2026
PubMed
概括
此摘要是机器生成的。

扩散性大B细胞淋巴瘤 (DLBCL) 治疗的目标是治愈,大约三分之二的患者实现长期存活. 进展包括向疗法和细胞治疗,但研究继续改善复发性或耐火性DLBCL的结果.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K

相关实验视频

Last Updated: Mar 11, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.6K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学

背景情况:

  • 扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的B细胞癌症,也是最常见的淋巴瘤亚型.
  • 目前的治疗方法提供治疗意图,大约66%的患者实现了持久的长期存活.
  • 治疗策略是根据风险调整的,考虑疾病阶段,预后因素和分子亚型.

研究的目的:

  • 概述扩散型大B细胞淋巴瘤 (DLBCL) 的当前管理策略.
  • 讨论基于疾病特征和患者子组的治疗方法.
  • 突出正在进行的DLBCL新疗法的研究.

主要方法:

  • 对DLBCL当前治疗指南和临床实践的审查.
  • 描述一线,二线和息治疗模式.
  • 在临床试验中提到新兴的细胞和双特异性疗法.

主要成果:

  • 以人环素为基础的化学疗法与rituximab是标准的初始疗法.
  • 特定的亚型 (例如,激活B细胞) 和遗传重组 (Myc,BCL-2) 指导治疗的强化.
  • 化学抗原受体 (CAR) T细胞疗法和自主干细胞移植的救援化疗是疾病复发的关键.

结论:

  • 尽管采取了适应风险的策略,但至少有三分之一的DLBCL患者复发.
  • 息选择包括双特异性抗体和抗体与药物合物,用于耐火病例.
  • 包括细胞和双特异性药物在内的研究疗法正在被整合到前线治疗中,以改善DLBCL的结果.